A-TANGO

A-TANGO

Investigación

Barcelona, Catalonia 287 seguidores

A-TANGO performs Phase II clinical studies of a new combinatorial therapy, G-TAK, to fight end-stage cirrhosis and ACLF.

Sobre nosotros

About 30,000 Europeans die every year from alcohol-related cirrhosis. In its final stages, the disease leads to acute-on-chronic liver failure (ACLF), a syndrome characterised by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase II clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy “G-TAK”. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

Sector
Investigación
Tamaño de la empresa
De 51 a 200 empleados
Sede
Barcelona, Catalonia
Tipo
Organización sin ánimo de lucro
Fundación
2021
Especialidades
hepatology, ACLF, liver disease, liver research, gastroenterology, alcoholic hepatitis, acute-on-chronic liver failure, Toll-like receptor, G-CSF, cirrhosis, TAK242, hepatocyte proliferation, inflammation, biomarkers, alcohol-related cirrhosis, granulocyte colony-stimulating factor, multiorgan failure, late stage clinical trials y Phase 2 clinical trials

Ubicaciones

  • Principal

    Travessera de Gràcia, 11

    7th floor

    Barcelona, Catalonia 08021, ES

    Cómo llegar

Empleados en A-TANGO

Actualizaciones

Páginas similares

Buscar empleos